Papa Medical Inc. Reports 26.1% Revenue Decline in Q3 2025 Amid Regulatory Challenges

Papa Medical Inc. reported a significant decline in financial performance for the third quarter of 2025, with revenues totaling $7.37 million, a decrease of 26.1% from $9.97 million in the same period of 2024. For the nine months ending September 30, 2025, revenues increased to $39.95 million, up 46.4% from $27.28 million year-over-year. The company's gross profit for the quarter fell to $1.42 million, down 41.8% from $2.44 million, while the gross profit margin decreased to 19.3% from 24.5%. The decline in quarterly performance was attributed to new regulations affecting product packaging, which slowed order placements.

Operating expenses rose sharply, with total operating expenses for the third quarter reaching $2.70 million, a 35.4% increase from $1.99 million in the prior year. This increase was driven by higher selling and marketing expenses, which surged by 35.2% to $1.63 million, and general and administrative expenses, which rose by 64.3% to $0.75 million. The company reported an operating loss of $1.28 million for the quarter, compared to an operating income of $0.44 million in the same period last year. Net income for the quarter was a loss of $0.82 million, contrasting with a profit of $0.30 million in 2024.

In terms of strategic developments, Papa Medical has been focusing on expanding its product offerings and market presence. The company has been actively involved in the research and development of new products, including a new series of E-vapors, which contributed to a 68.3% increase in research and development expenses for the quarter. The company also reported a significant increase in its customer base for Hemp cannabinoid E-vapors, which accounted for 80.3% of total revenues in the third quarter.

Operationally, the company faced challenges with cash flow, reporting a net cash outflow of $3.34 million from operating activities for the nine months ended September 30, 2025, compared to $0.69 million in the same period of 2024. Cash and cash equivalents decreased to $0.86 million from $4.75 million at the end of 2024. The company anticipates that its existing cash balances and expected cash flows will be sufficient to meet working capital requirements for at least the next twelve months, although it may seek additional financing to support growth initiatives.

Looking ahead, Papa Medical remains focused on navigating regulatory challenges and expanding its market share in the Hemp and consuming E-vapors sectors. The company is optimistic about its growth potential, driven by increased demand for its products and ongoing product development efforts. However, management acknowledges that future performance will be influenced by market conditions, regulatory developments, and the company's ability to adapt to changing consumer preferences.